Pascal Soriot, AstraZeneca CEO (David Zorrakino/Europa Press via AP Images)
August 8, 2022 01:58 PM EDTUpdated August 9, 01:51 PM
Pharma
FDA+

As­traZeneca and Dai­ichi Sankyo sprint to mar­ket af­ter FDA clears En­her­tu in just two weeks

Nicole DeFeudis

Editor

Reg­u­la­tors didn’t keep As­traZeneca and Dai­ichi Sankyo wait­ing long at all for their lat­est En­her­tu ap­proval.

The part­ners pulled a win on Fri­day in HER2 …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times